32. Clinical and paraclinical characteristics of patients with poorly differentiated and undifferentiated thyroid cancer at Viet Nam National Cancer Hospital during 2018 - 2023

Nguyen Van Dang, Tieu Van Luc

Main Article Content

Abstract

Thyroid cancer (TC) is the most common malignancy of the endocrine system, accounting for 90% of cases. The majority (> 95%) of thyroid cancers originate from follicular cells, with less than 5% originating from parafollicular cells. Thyroid cancer of follicular origin is divided into three main types: well-differentiated, poorly differentiated, and undifferentiated. Poorly differentiated and undifferentiated thyroid cancers have distinct clinical and paraclinical features. The study was conducted on 16 patients with poorly differentiated and undifferentiated thyroid cancers treated at the Head and Neck Radiation Department of Viet Nam National Cancer Hospital from January 2018 to December 2023. The average age was 67.4 ± 11.2 years. Common reasons for hospital admission included palpable neck mass (50%), cervical lymphadenopathy (31.25%), and dysphagia (12.5%). Clinically, the tumors and lymph nodes were often firm and had limited mobility. On ultrasound, the common features of the tumors were hypoechogenicity (87.5%), microcalcifications (93.75%), and indistinct margins (93.75%). The rate of cervical lymph node diagnosis on ultrasound was 93.75%. The rate of positive and suspicious fine-needle aspiration cytology for poorly differentiated thyroid cancer was 100%.

Article Details

References

1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014; 140(4): 317-322. doi:10.1001/jamaoto.2014.1.
2. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004; 114(3): 393-402. doi:10.1097/00005537-200403000-00001.
3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi:10.3322/caac.21660.
4. DRL Heitz PU, The International Agency for Research on Cancer. WHO Classification of Tumours of Endocrine Organs. IARC Press; 2004.
5. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007; 31(8): 1256-1264. doi:10.1097/PAS.0b013e3180309e6a.
6. Bongiovanni M, Fadda G, Faquin WC. Poorly Differentiated Thyroid Carcinoma. In: Ali SZ, Cibas ES, eds. The Bethesda System for Reporting Thyroid Cytopathology. Springer International Publishing; 2018: 177-188. doi:10.1007/978-3-319-60570-8_10.
7. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005; 103(7): 1330-1335. doi:10.1002/cncr.20936.
8. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. Cancer. 2000; 89(1): 202-217. doi:10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A.
9. Ibrahimpasic T, Ghossein R, Carlson DL, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2014; 99(4): 1245-1252. doi:10.1210/jc.2013-3842.
10. Lê Văn Quảng. Nhận xét đặc điểm lâm sàng và các phương pháp điều trị ung thư tuyến giáp tại Bệnh viện K từ năm 1992-2000. Tạp chí Y học.:323-326.
11. Suh HJ, Moon HJ, Kwak JY, Choi JS, Kim EK. Anaplastic Thyroid Cancer: Ultrasonographic Findings and the Role of Ultrasonography-Guided Fine Needle Aspiration Biopsy. Yonsei Med J. 2013; 54(6): 1400-1406. doi:10.3349/ymj.2013.54.6.1400.
12. Ahmed S, Ghazarian MP, Cabanillas ME, et al. Imaging of Anaplastic Thyroid Carcinoma. American Journal of Neuroradiology. 2018; 39(3): 547-551. doi:10.3174/ajnr.A5487.